Cells Tissues Organs

 

Epithelial-Mesenchymal Transition and Colorectal Cancer: Gaining Insights into Tumor Progression Using LIM 1863 Cells

Bates R.C. · Pursell B.M. · Mercurio A.M.

Author affiliations

Department of Cancer Biology, University of Massachusetts Medical School, Worcester, Mass., USA

Keywords: Colorectal cancerEpithelial-mesenchymal transitionIntegrinsCytokinesTumor progression

Related Articles for ""
Cells Tissues Organs 2007;185:29–39
https://doi.org/10.1159/000101300

Log in to MyKarger to check if you already have access to this content.


Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve

  • Unlimited fulltext viewing of this article
  • Organize, annotate And mark up articles
  • Printing And downloading restrictions apply

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Received: February 10, 2006
Accepted: September 29, 2006
Published online: June 25, 2007
Issue release date: June 2007

Number of Print Pages: 11
Number of Figures: 4
Number of Tables: 0

ISSN: 1422-6405 (Print)
eISSN: 1422-6421 (Online)

For additional information: https://www.karger.com/CTO

Abstract

In addition to allowing epithelial cells to escape the structural constraints imposed by tissue architecture and adopt a phenotype more amenable to cell movement, it is now recognized that the epithelial-mesenchymal transition (EMT) may also represent a critical component permitting the progression of carcinomas towards invasive and metastatic disease. However, data supporting the actual occurrence of EMT in specific solid tumors and its relevance to the process of progression of these cancers has been scant. Despite an extensive knowledge of the genetic basis for colorectal cancer, the translation of this information into effective treatments has been limited. Clearly, there is a desperate need for new and improved therapies and since the switch to a metastatic phenotype is critical for outcome, it is of paramount importance to elucidate the biology that underlies the progression of this disease. Thus, the unique LIM 1863 model for studying the EMT of colorectal carcinoma has been used to both substantiate the importance of the transition for this cancer type and to identify molecular events that contribute to disease progression. Importantly, it has emerged that not only does EMT enhance migratory capacity, but also elicits additional selective advantages to colonic tumor cells. Specifically, the acquisition of autocrine growth factor signaling loops, mechanisms to evade apoptosis, and expression of specific integrins allowing invasive cells to interact with interstitial matrices and sustain activation of TGF-β combine to provide a compelling new biochemical framework for understanding how EMT contributes to tumor evolution.

© 2007 S. Karger AG, Basel


References

  1. Andre, T., L. Kotelevets, J.C. Vaillant, A.M. Coudray, L. Weber, S. Prevot, R. Parc, C. Gespach, E. Chastre (2000) Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 86: 174–181.
    External Resources
  2. Arias, A.M. (2001) Epithelial mesenchymal interactions in cancer and development. Cell 105: 425–431.
    External Resources
  3. Baier, P.K., G. Wolff-Vorbeck, S. Eggstein, U. Baumgartner, T.U. Hopt (2005) Cytokine expression in colon carcinoma. Anticancer Res 25: 2135–2139.
    External Resources
  4. Barth, R.J., Jr., B.J. Camp, T.A. Martuscello, B.J. Dain, V.A. Memoli (1996) The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival. Cancer 78: 1168–1178.
    External Resources
  5. Bates, R.C. (2003) Gastrointestinal matrix, organization and significance; in Johnson, L.R. (ed): Encyclopedia of Gastroenterology. San Diego, Elsevier Science, pp 219–223.
  6. Bates, R.C., A. Buret, D.F. van Helden, M.A. Horton, G.F. Burns (1994) Apoptosis induced by inhibition of intercellular contact. J Cell Biol 125: 403–415.
    External Resources
  7. Bates, R.C., L.F. Lincz, G.F. Burns (1995) Involvement of integrins in cell survival. Cancer Metastasis Rev 14: 191–203.
    External Resources
  8. Bates, R.C., N.S. Edwards, J.D. Yates (2000) Spheroids and cell survival. Crit Rev Oncol Hematol 36: 61–74.
    External Resources
  9. Bates, R.C., J.D. Goldsmith, R.E. Bachelder, C. Brown, M. Shibuya, P. Oettgen, A.M. Mercurio (2003) Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids. Curr Biol 13: 1721–1727.
    External Resources
  10. Bates, R.C., A.M. Mercurio (2003) Tumor necrosis factor-α stimulates the epithelial to mesenchymal transition of human colonic organoids. Mol Biol Cell 14: 1790–1800.
    External Resources
  11. Bates, R.C., D.I. Bellovin, C. Brown, E. Maynard, B. Wu, H. Kawakatsu, D. Sheppard, P. Oettgen, A.M. Mercurio (2005) Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 115: 339–347.
    External Resources
  12. Bhowmick, N.A., M. Ghiassi, A. Bakin, M. Aakre, C.A. Lundquist, M.E. Engel, C.L. Arteaga, H.L. Moses (2001) Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a Rho-A-dependent mechanism. Mol Biol Cell 12: 27–36.
    External Resources
  13. Brabletz, T., A. Jung, S. Reu, M. Porzner, F. Hlubeck, L.A. Kunz-Schugart, R. Knuechel, T. Kirchner (2001) Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor microenvironment. Proc Natl Acad Sci USA 98: 10356–10361.
    External Resources
  14. Brabletz, T., F. Hlubek, S. Spaderna, O. Schmalhofer, E. Hiendlmeyer, A. Jung, T. Kirchner (2005a) Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and β-catenin. Cells Tissues Organs 179: 56–65.
    External Resources
  15. Brabletz, T., A. Jung, S. Spaderna, F. Hlubek, T. Kirchner (2005b) Migrating cancer stem cells – an integrated concept of malignant tumour progression. Nat Rev Cancer 5: 744–749.
    External Resources
  16. Breuss, J.M., N. Gillett, L. Lu, D. Sheppard, R. Pytela (1993) Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. J Histochem Cytochem 41: 1521–1527.
    External Resources
  17. Breuss, J.M., J. Gallo, H.M. DeLisser, I.V. Klimanskaya, H.G. Folkesson, J.F. Pittet, S.L. Nishimura, K. Aldape, D.V. Landers, W. Carpenter, N. Gillett, D. Sheppard, M.A. Matthay, S.M. Albelda, R.H. Kramer, R. Pytela (1995) Expression of the β6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci 108: 2241–2251.
    External Resources
  18. Busk, M., R. Pytela, D. Sheppard (1992) Characterization of the integrin αvβ6 as a fibronectin-binding protein. J Biol Chem 267: 5790–5796.
    External Resources
  19. Calvert, P.M., H. Frucht (2002) The genetics of colorectal cancer. Ann Intern Med 137: 603–612.
    External Resources
  20. Csiszar, A., T. Szentes, B. Haraszti, W. Zou, D. Emilie, G.G. Petranyi, E. Pocsik (2001) Characterization of cytokine mRNA expression in tumor-infiltrating mononuclear cells and tumor cells freshly isolated from human colorectal carcinomas. Eur Cytokine Netw 12: 87–96.
    External Resources
  21. Csiszar, A., T. Szentes, B. Haraszti, A. Balazs, G.G. Petranyi, E. Pocsik (2004) The pattern of cytokine gene expression in human colorectal carcinoma. Pathol Oncol Res 10: 109–116.
    External Resources
  22. de Caestecker, M.P., E. Piek, A.B. Roberts (2000) Role of transforming growth factor-β signaling in cancer.J Natl Cancer Inst 92: 1388–1402.
  23. Diaz-Rubio, E. (2004) New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 9: 282–294.
    External Resources
  24. Engle, S.J., J.B. Hoying, G.P. Boivin, I. Ormsby, P.S. Gartside, T. Doetschman (1999) Transforming growth factor beta 1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59: 3379–3386.
    External Resources
  25. Etoh, T., K. Shibuta, G.F. Barnard, S. Kitano, M. Mori (2000) Angiogenin expression inhuman colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res 6: 3545–3551.
    External Resources
  26. Fearon, E.R., B. Vogelstein (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759–767.
    External Resources
  27. Friedl, P., K. Wolf (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3: 362–374.
    External Resources
  28. Friedl, P., Y. Hegerfeldt, M. Tusch (2004) Collective cell migration in morphogenesis and cancer. Int J Dev Biol 48: 441–449.
    External Resources
  29. Fujimoto, K., H. Sheng, J. Shao, R.D. Beauchamp (2001) Transforming growth factor-β1 promotes invasiveness after cellular transformation with activated ras in intestinal epithelial cells. Exp Cell Res 266: 239–249.
    External Resources
  30. Gold, L.I. (1999) The role of transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 10: 303–360.
    External Resources
  31. Goldberg, R.M. (2005) Advances in the treatment of metastatic colon cancer. Oncologist 10(suppl 3): 40–48.
    External Resources
  32. Goss, K.H., J. Groden (2000) Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 18: 1967–1979.
    External Resources
  33. Gotzmann, J., M. Mikula, A. Eger, R. Schulte-Hermann, R. Foisner, H. Beug, W. Mikulits (2004) Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res 566: 9–20.
    External Resources
  34. Hamidi, S., T. Salo, T. Kainulainen, J. Epstein, K. Lerner, H. Larjava (2000) Expression of alpha(v)beta6 integrin in oral leukoplakia. Br J Cancer 82: 1433–1440.
    External Resources
  35. Hanahan, D., R.A. Weinberg (2000) The hallmarks of cancer. Cell 100: 57–70.
    External Resources
  36. Hasumi, Y., H. Mizukami, M. Urabe, T. Kohno, K. Takeuchi, A. Kume, M. Momoeda, H. Yoshikawa, T. Tsuruo, M. Shibuya, Y. Taketani, K. Ozawa (2002) Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 62: 2019–2023.
    External Resources
  37. Hayward, I.P., R.H. Whitehead (1992) Patterns of growth and differentiation in the colon carcinoma cell line LIM 1863. Int J Cancer 51: 1–8.
    External Resources
  38. Hayward, I.P., R.H. Whitehead, L. Ward, R. Gianello, P. Dempsey, R. Bates, G.F. Burns (1995) Effect of TGF-beta on differentiated organoids of the colon carcinoma cell line LIM 1863. Immunol Cell Biol 73: 249–257.
    External Resources
  39. Hoshida, T., M. Sunamura, D.G. Duda, S. Egawa, S. Miyazaki, R. Shineha, H. Hamada, H. Ohtani, S. Satomi, S. Matsuno (2000) Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. Pancreas 25: 111–121.
    External Resources
  40. Hsu, S., F. Huang, M. Hafez, S. Winawer, E. Friedman (1994) Colon carcinoma cells switch their response to transforming growth factor beta 1 with tumor progression. Cell Growth Differ 5: 267–275.
    External Resources
  41. Hynes, R.O. (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11–25.
    External Resources
  42. Hynes, R.O. (2002) Integrins: bi-directional allosteric signaling machines. Cell 110: 673–687.
    External Resources
  43. Janda, E., K. Lehmann, I. Killisch, M. Jechlinger, M. Herzig, J. Downward, H. Beug, S. Grunert (2002) Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis: dissection of ras signaling pathways. J Cell Biol 156: 299–314.
    External Resources
  44. Kemperman, H., M.H. Driessens, G. LaRiviere, A.M. Meijne, E. Roos (1995) Adhesion mechanisms in liver metastasis formation. Cancer Surv 24: 67–79.
    External Resources
  45. Kinzler, K., B. Vogelstein (1996) Lessons from hereditary colorectal cancer. Cell 87: 159–170.
    External Resources
  46. Kuo, C.J., F. Farnebo, E.Y. Yu, R. Christofferson, R.A. Swearingen, R. Carter, H.A. von Recum, J. Yuan, J. Kamihara, E. Flynn, R. D’Amato, J. Folkman, R.C. Mulligan (2001) Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 98: 4606–4610.
  47. Leek, R.D., C.E. Lewis, R. Whitehouse, M. Greenall, J. Clarke, A.L. Harris (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56: 4625–4629.
    External Resources
  48. Lehmann, K., E. Janda, C.E. Pierreux, M. Rytomaa, A. Schulze, M. McMahon, C.S. Hill, H. Beug, J. Downward (2000) Raf induces TGFβ production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev 14: 2610–2622.
    External Resources
  49. Liotta, L., E.C. Kohn (2001) The microenvironment of the tumor-host interface. Nature 411: 375–379.
    External Resources
  50. Mahasreshti, P.J., J.G. Navarro, M. Kataram, M.H. Wang, D. Carey, G.P. Siegal, M.N. Barnes, D.M. Nettleback, R.D. Alvarez, A. Hemminki, D.T. Curiel (2001) Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res 7: 2057–2066.
    External Resources
  51. Markowitz, S.D., A.B. Roberts (1996) Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev 7: 93–102.
    External Resources
  52. Markowitz, S.D., D.M. Dawson, J. Willis, J.K.V. Willson (2002) Focus on colon cancer. Cancer Cell 1: 233–236.
    External Resources
  53. Marshall, J. (2005) The role of bevacizumab as a first-line therapy for colon cancer. Semin Oncol 32: 43–47.
    External Resources
  54. Mercurio, A.M., R.E. Bachelder, R.C. Bates, J. Chung (2004) Autocrine signaling in carcinoma: VEGF and the α6β4 integrin. Semin Cancer Biol 14: 115–122.
    External Resources
  55. Munger, J.S., X. Huang, H. Kawakatsu, M.J. Griffiths, S.L. Dalton, J. Wu, J.F. Pittet, N. Kaminski, C. Garat, M.A. Matthay, D.B. Rifkin, D. Sheppard (1999) The integrin αvβ6 binds and activates latent TGFβ1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96: 319–328.
    External Resources
  56. Nawshad, A., D. LaGamba, A. Polad, E.D. Hay (2005) Transforming growth factor-β signaling during epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells Tissues Organs 179: 11–23.
    External Resources
  57. Naylor, M.S., G.W. Stamp, W.D. Foulkes, D. Eccles, F.R. Balkwill (1993) Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 91: 2194–2206.
    External Resources
  58. Oft, M., J. Peli, C. Rudaz, H. Schwarz, H. Beug, E. Reichmann (1996) TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10: 2462–2477.
    External Resources
  59. Oft, M., K.H. Heider, H. Berg (1998) TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8: 1243–1252.
    External Resources
  60. Papadakis, K.A., S.R. Targan (2000) Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119: 1148–1157.
    External Resources
  61. Pilewski, J.M., J.D. Latoche, S.M. Arcasoy, S.M. Albelda (1997) Expression of integrin cell adhesion receptors during human airway epithelial repair in vivo. Am J Pathol 273: L256–L263.
    External Resources
  62. Prieto, A.L., G.M. Edelman, K.L. Crossin (1993) Multiple integrins mediate cell attachment to cytoactin/tenascin. Proc Natl Acad Sci USA 90: 10154–10158.
    External Resources
  63. Raz, A. (1988) Adhesive properties of metastasizing tumor cells. Ciba Found Symp 141: 323–330.
  64. Reichmann, E., H. Schwarz, E.M. Deiner, I. Leitner, M. Eilers, M. Busslinger, H. Beug (1992) Activation of an inducible c-fos ER fusion protein causes loss of epithelial polarity and triggers epithelial-fibroblastoid conversion. Cell 71: 1103–1116.
    External Resources
  65. Regezi, J.A., D.M. Ramos, R. Pytela, N.P. Dekker, R.C.K. Jordan (2002) Tenascin and β6 integrin are overexpressed in floor of mouth in situ carcinomas and invasive squamous cell carcinomas. Oral Oncol 38: 332–336.
    External Resources
  66. Savagner, P. (2001) Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 23: 912–923.
    External Resources
  67. Schiott, A., A.C.M. Johansson, B. Widegreen, H.O. Sjorgen, M. Lindvall (2000) Effects of transforming growth factor β1 expression in a rat colon carcinoma: growth inhibition, leukocyte infiltration and production of interleukin-10 and tumor necrosis factor α. Cancer Immunol Immunother 48: 579–587.
    External Resources
  68. Schultze, A., K. Lehmann, H.B.J. Jeffries, M. McMahon, J. Downward (2001) Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev 15: 981–994.
    External Resources
  69. Sunderkotter, C., K. Steinbrink, M. Goebeler, R. Bhardwaj, C. Sorg (1994) Macrophages and angiogenesis. J Leukoc Biol 55: 410–422.
    External Resources
  70. Takayama, K.K., H. Ueno, Y. Nakanishi, T. Sakamoto, K. Inoue, K. Shimizu, H. Oohashi, N. Hara (2000) Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 60: 2169–2177.
    External Resources
  71. Thiery, J.P. (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442–454.
    External Resources
  72. Thiery, J.P. (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740–746.
    External Resources
  73. Tuxhorn, J.A., G.E. Ayala, D.R. Rowley (2001) Reactive stroma in prostate cancer progression. J Urol 166: 2472–2483.
    External Resources
  74. Vogelstein, B, E. Fearon, S. Hamilton, S.E. Kern, A.C. Preisinger, M. Leppert, Y. Nakamura, R. White, A.M. Smits, J.L. Bos (1988) Genetic alterations during colorectal tumor development. N Engl J Med 319: 525–532.
    External Resources
  75. Wakefield, L.M., A.B. Roberts (2002) TGF-β signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12: 22–29.
    External Resources
  76. Wang, F., V.M. Weaver, O.W. Petersen, C.A. Larabell, S. Dedhar, P. Briand, R. Lupu, M.J. Bissell (1998) Reciprocal interactions between beta-1 integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci USA 95: 14821–14826.
    External Resources
  77. Warren, R.S., H. Yuan, M.R. Matli, N.A. Gillett, N. Ferrara (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95: 1789–1797.
    External Resources
  78. Watanabe, T., T.T. Wu, P.J. Catalano, T. Ueki, R. Satriano, D.G. Haller, A.B. Benson 3rd (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344: 1196–1206.
    External Resources
  79. Weaver, V.M., O.W. Petersen, F. Wang, C.A. Larabell, P. Briand, C. Damsky, M.J. Bissell (1997) Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 137: 231–245.
    External Resources
  80. Whitehead, R.H., J.K. Jones, A. Gabriel, R.E. Lukies (1987) A new colon carcinoma cell line (LIM 1863) that grows as organoids with spontaneous differentiation into crypt-like structures in vitro. Cancer Res 47: 2683–2689.
    External Resources
  81. Wu, S., C.M. Boyer, R.S. Whitaker, A. Berchuck, J.R. Weiner, J.B. Weinberg, R.C. Bast Jr. (1993) Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 53: 1939–1944.
    External Resources
  82. Yang, W., S. Arii, A. Mori, K. Furumoto, T. Nakao, N. Isobe, T. Murata, H. Onodera, M. Imamura (2001) sFlt-1 gene-transfected fibroblasts: a wound specific gene therapy inhibits local cancer recurrence. Cancer Res 61: 7840–7845.
    External Resources
  83. Yue, J., K.M. Mulder (2001) Transforming growth factor-β signal transduction in epithelial cells. Pharmacol Ther 91: 1–34.
    External Resources
  84. Zambruno, G., P.C. Marchisio, A. Marconi, C. Vaschieri, A. Melchiori, A. Giannetti, M. DeLuca (1995) Transforming growth factor-beta 1 modulates beta 1 and beta 5 integrin receptors and induces the de novo expression of the alpha v beta 6 heterodimer in normal human keratinocytes: implications for wound healing. J Cell Biol 129: 853–865.
    External Resources
  85. Zbar, A.P. (2004) The immunology of colorectal cancer. Surg Oncol 13: 45–53.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Paper

Received: February 10, 2006
Accepted: September 29, 2006
Published online: June 25, 2007
Issue release date: June 2007

Number of Print Pages: 11
Number of Figures: 4
Number of Tables: 0

ISSN: 1422-6405 (Print)
eISSN: 1422-6421 (Online)

For additional information: https://www.karger.com/CTO

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2007, Vol.185, No. 1-3

June 2007

Article

Recommend This
Stay Up to Date Banner Stay Up to Date Banner
TOP